These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29309107)

  • 1. Cutaneous side effects caused by treatment for inflammatory bowel disease.
    Tarabar D; Kandolf-Sekulović L; Tatomirović Ž; Mijušković Ž; Milenković Z; Tarabar O; Pecelj-Broćić T
    Vojnosanit Pregl; 2016 Apr; 73(4):382-9. PubMed ID: 29309107
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
    Stobaugh DJ; Deepak P
    Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reproductive issues in inflammatory bowel disease.
    Saha S; Esposti SD
    Med Health R I; 2009 Apr; 92(4):148-51. PubMed ID: 19452759
    [No Abstract]   [Full Text] [Related]  

  • 4. [Benefits and risks of immunosuppression in chronic inflammatory bowel diseases].
    Rogler G
    Dtsch Med Wochenschr; 2008 Sep; 133(38):1917-21. PubMed ID: 18785084
    [No Abstract]   [Full Text] [Related]  

  • 5. Listeria monocytogenes infection in patients with inflammatory bowel diseases receiving anti-tumor necrosis factor therapy.
    Ramos JM; García-Sepulcre MF; Masiá M; Brotons A; Grau MC; Gutiérrez F
    Rev Esp Enferm Dig; 2010 Oct; 102(10):614-6. PubMed ID: 21039077
    [No Abstract]   [Full Text] [Related]  

  • 6. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.
    Sandborn WJ
    Am J Gastroenterol; 1996 Mar; 91(3):423-33. PubMed ID: 8633486
    [No Abstract]   [Full Text] [Related]  

  • 7. Position statement: immunomodulator therapy for inflammatory Bowel disease.
    Lavy A; Chowers Y; Odes HS; Eliakim R;
    Isr Med Assoc J; 2003 Mar; 5(3):164-9. PubMed ID: 12725133
    [No Abstract]   [Full Text] [Related]  

  • 8. Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions.
    Soh JS; Yun WJ; Kim KJ; Won CH; Park SH; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Kim JH
    Inflamm Bowel Dis; 2015 Apr; 21(4):832-9. PubMed ID: 25789922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events of IBD therapies.
    Scribano ML
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S210-1. PubMed ID: 18816669
    [No Abstract]   [Full Text] [Related]  

  • 10. The future of inflammatory bowel disease care.
    Sandborn WJ
    Rev Gastroenterol Disord; 2009; 9(3):E69-77. PubMed ID: 19898267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of immunosuppressive drugs during pregnancy.
    Bermas BL; Hill JA
    Arthritis Rheum; 1995 Dec; 38(12):1722-32. PubMed ID: 8849343
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug-induced nephrotoxicity in inflammatory bowel disease.
    Oikonomou KA; Kapsoritakis AN; Stefanidis I; Potamianos SP
    Nephron Clin Pract; 2011; 119(2):c89-94; discussion c96. PubMed ID: 21677443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory bowel disease.
    Podolsky DK
    N Engl J Med; 2002 Aug; 347(6):417-29. PubMed ID: 12167685
    [No Abstract]   [Full Text] [Related]  

  • 15. Decrease in factor V activity: a new adverse effect of purine analogs in inflammatory bowel diseases?
    Poupeney S; Dray X; Reignier S; Vahedi K; Alhenc M; Belluci S; Marteau P
    Inflamm Bowel Dis; 2008 Jul; 14(7):1024-5. PubMed ID: 18286642
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug resistance in inflammatory bowel diseases.
    Moreau J; Mas E
    Curr Opin Pharmacol; 2015 Dec; 25():56-61. PubMed ID: 26645664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity of 6-mercaptopurine/azathioprine in patients with inflammatory bowel disease.
    Marion JF
    Inflamm Bowel Dis; 1998 May; 4(2):116-7. PubMed ID: 9687219
    [No Abstract]   [Full Text] [Related]  

  • 18. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.
    Lowry PW; Franklin CL; Weaver AL; Szumlanski CL; Mays DC; Loftus EV; Tremaine WJ; Lipsky JJ; Weinshilboum RM; Sandborn WJ
    Gut; 2001 Nov; 49(5):656-64. PubMed ID: 11600468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease.
    Daperno M; Sostegni R; Canaparo R; Serpe L; Lavagna A; Crocellà L; Castagno F; Vernetto A; Rigazio C; Ercole E; D'Antico S; Pera A; Zara G; Rocca R
    Aliment Pharmacol Ther; 2009 Oct; 30(8):843-53. PubMed ID: 19650826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.